MrC's Smallcap Sweeps for Oct 2020

[MrContrarian]

Smallcap Sweep. 28-Oct-20
Shoe pasty

Maestrano (MNO) Q to Sept rev £436k (£101k). EBITDA -£346k (-£316k). "The board continues to be delighted with not only sales growth but also customer appetite for our solutions..." [SP=9.5 Cap=15m]
Mirriad Advertising (MIRI) two-year commercial agreement with one of the largest and best-known US-based content producers and distributors to develop its in-video advertising on a number of entertainment series. No immediate income, contact sets out T&C for doing business. [SP=32 Cap=68m]
Amiad (AFS) CFO leaves end of year. He is thanked. [SP=240 Cap=73m]
WANdisco (WAND) go-to-market launch of LiveData Platform for Azure, in public preview. "The Platform is being launched by Microsoft as the preferred solution for Hadoop data lake migrations to Azure." All in line with mgmt expectations. [SP=450 Cap=236m]
EKF Diagnostics (EKF) two year marketing and distribution agreement with Kantaro Biosciences. EKF will have exclusive rights to market and distribute COVID-SeroKlir covid IgG (single) antibody test kit in the UK and Germany and non-exclusive rights in Europe. Also non-exclusive rights to distribute COVID-SeroIndex (quantitative) test across UK and Europe for research. [SP=64.5 Cap=293m]
Zoetic (ZOE) significant order to roll out Chill range of tobacco-substitute CBD products in a number of convenience store outlets throughout the USA. Sale of legacy DTU and the Kansas Nitrogen Assets will miss long-stop of Oct 31. [SP=44.5 Cap=87m]
Tribal (TRB) guides FY comfortably ahead of market expectations* with rev in line at c.£72m and adj EBITDA c.£14.8m. Will reinstate divs with interim div 1.1p. * rev £72.1m, adj EBITDA £13.7m. [SP=67 Cap=138m]
Centaur Media (CAU) Q3 'resilinet' with rev down 16% (Q2 down 24%). Guides FY rev-cont at least £32m and adj EBITDA margin c.10%. Further exceptional charge of £0.6m. In line? No guidance. [SP=21 Cap=33m]
SysGroup (SYS) guides H1 rev broadly flat, adj EBITDA up at least 15%. "This performance has continued into H2." Guides 'a good outcome' for FY. [SP=35 Cap=16m]
Omega Diagnostics (ODX) guides H1 in line with rev down 29%, EBITDA -£1.3m. Expects 'significantly improved performance' in H2. Various updates including covid tests. [SP=91.11 Cap=163m]
Shoe Zone (SHOE) gloomy. Guides FY rev down 24%, pretax -£10 to 12m. . Tiers 2 and 3 covid regions 'greatly impacted'. One of the legacy pension schemes will need extra funding. No divs until at least the 2024/25. "Very difficult at this stage to provide meaningful guidance on the future outlook." [SP=44.9 Cap=22m]
ULS Technology (ULS) guides H1(Sep) rev down 31%, U/L pretax £0.1m. Co "delighted with the resilience of the Group". [SP=53.24 Cap=35m]
Image Scan (IGE) guides FY(Sep) rev up 50% and pre-tax trading profit £112k (-£402k) above prev guided £0 to £100k. [SP=2.37 Cap=3m]

In line: FRAN
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 29-Oct-20


Hornby (HRN) H1 rev up 33%, pretax £17k (-£2.5m). Outlook 'hard to tell'. [SP=33 Cap=55m]
Kape Technologies (KAPE) £89m raised in oversubscribed placing last night at 150p, a 1.6% discount. [SP=152.7 Cap=246m]
Kromek (KMK) CFO scarpers. He is thanked. [SP=12.2 Cap=42m]
Filtronic (FTC) delivery delays mean rev broadly flat. "Slow order intake has been experienced in the public safety market as our lead customer continues to experience in-field rollout constraints. New business acquisition remains a challenge as opportunities for customer engagement remain constrained." [SP=9.35 Cap=20m]
Tiziana Life Sciences (TILS) confirms Accustem Sciences demerger timetable. Ex-entitlement date 2 Nov. [SP=155 Cap=300m]
Foxtons (FOXT) Q3 rev down 10%, sales commission pipeline highest in 3 years. "Remains cautious as economic uncertainty causes more sales transactions to fall through and is putting downward pressure on rents." [SP=34.3 Cap=113m]
MTI Wireless Edge (MWE) wins $1.5m follow-on order in Russia. [SP=43 Cap=38m]
OTAQ (OTAQ) guides H1(Sep) rev and EBITDA up by unspecified amounts. Guides FY rev up c. 17% and EBITDA up c.11%. ""Trading in this period however has been challenging and has resulted in the expected timescales for our growth ambitions being extended due to limitations in our ability to engage with new customers." [SP=37.5 Cap=11m]
Magnit (MGNT) Q3 rev up 12%, LFL up 7%, in Roubles. Confirms store opening and redesign guidance but cuts capex. [SP=NA Cap=NA]

In line: BIOM
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian

[MrContrarian]

Smallcap Sweep. 30-Oct-20
Low altitude warning

Volvere (VLE) £10m placing and PrimaryBib offer at 1350, a nil disc, ' in furtherance of the Company's investing strategy'. VLE returned cash only 18 months ago! [SP=1302 Cap=25m]
Minds + Machines (MMX) the accounting investigation finds that $928k should been counted as a deposit and not rev in FY19. Also 2 additional contracts in FY19 totalling $790k where receipts were incorrectly categorised as revenue. CEO and CFO resign. Proposed tender offer postponed. [SP=4.05 Cap=37m]
Supply@ME Capital (SYME) decides to partner on an exclusive basis with only one investment fund whose intention is to subscribe for the whole of the first issuance (guides c.€300m) and become an ongoing partner. Slightly delays first issuance. [SP=0.43 Cap=141m]
Intelligent Ultrasound (MED) GE Healthcare's Voluson SWIFT ultrasound machine using MED's ScanNav Assist AI technology, has receive clearance from the FDA for sale in the USA. [SP=14.5 Cap=39m]
Altitude Group (ALT) FY(Mar) pretax -£2.7m(15 months) (£2.7m). Net cash £2.4m. "onfident that Altitude has sufficient financial resources and liquidity to see the business through to more normalised market conditions assuming that the steady recovery in the promotional products market place as witnessed since June 2020 continues, whilst accepting that there remains material uncertainty as to the future continuation, rate of recovery and overall economic impact of Covid-19 on the revenue." [SP=11.95 Cap=8m]
Oncimmune (ONC) FY and development update. "Negotiations with the NHS to adopt EarlyCDT Lung are approaching a conclusion with announcement expected soon of first contract to sell EarlyCDT Lung." [SP=180 Cap=114m]
De La Rue (DLAR) BoE uses option to extend banknote print contract by three years. [SP=136.4 Cap=266m]
Open Orphan (ORPH) wins 2-year contract with a tier 1 German pharma co. G'teed revenue, will start this month. That's today then. No €€€. [SP=25 Cap=166m]
Tekmar (TGP) guides H1 rev 10% down due to contact delays. No FY guidance. Extends FY by 6 months to Sept 2021 because of peak demand near FY end. New CEO review to eliver operational cost savings and further integration efficiencies. [SP=73 Cap=37m]

In line: AIBG
Notes SP & cap are 20m delayed
DYOR, E&OE etc etc. I may have a position in any or all of the shares covered.

RNSs
http://www.investegate.co.uk/index.aspx?limit=-1

@MrContrarian